Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma : an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials - Weisel, Katja (Department of Hematology. Oncology. Immunology. Rheumatology. and Pulmonology. Medical Clinic II) ; Majer, Istvan (Amgen Europe GmbH) ; DeCosta, Lucy (Amgen Ltd) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Goldschmidt, Hartmut (Internal Medicine V and National Center of Tumor Diseases. University Clinic Heidelberg) ; Ludwig, Heiz (Wilhelminen Cancer Research Institute (Viena, Àustria)) ; Campioni, Marco (Amgen Europe GmbH) ; Szabo, Zsolt (Amgen Europe GmbH) ; Dimopoulos, Meletios (School of Medicine. National and Kapodistrian University of Athens. Alexandra Hospital) ; Universitat Autònoma de Barcelona